Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions
Disease area: Respiratory infections, Thoracic oncology

Abstract

Introduction: The aim of this study was to evaluate the diagnostic utility of four tumor markers in patients with exudative pleural effusion.
Materials and methods: Pleural levels of carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA 15-3), carbohydrate antigen19-9 (CA19-9) and cancer antigen 125 (CA 125) were assayed prospectively in 50 patients with exudative pleural effusion (25 malignant and 25 benign) during 2008 – 2009 in Lung Disease and Tuberculosis Research Center (LTRC), Mashhad Iran.
Results: There were statistically significant differences between malignant and benign pleural effusions in CA15-3(p=0.00), CA19-9(p=0.00), and CEA (p=0.00) levels. There was no statistically significant difference in CA125 levels between two groups (p=0.06).The sensitivity (%) and specificity (%) of these tumor markers for differentiating malignant from benign effusions were as follows respectively:
CA 15-3 (84%, 100%), CA19-9 (68%, 96%), CEA (68%, 100%) and CA 125(4%, 84%).The highest sensitivity in the diagnosis of pleural malignancy was obtained with CA 15-3(84%).The highest specificity in the diagnosis of pleural malignancy was obtained with CA 15-3 and CA 19-9(100%).
Conclusion: The findings of this study suggest that pleural levels of tumor markers in addition to cytology can be useful in diagnosis of malignant pleural effusion.

Rating:

Share or cite this content

Citations should be made in the following way:
F. Rezaeetalab, D. Attaran, M. Towhidi, H. Akbari, S. Mohammadzadeh Lari, S. Shaabani (Islamic Republic Of Iran). Comparative evaluation of CA-125, CA 19-9, CA 15-3 and CEA in exudative benign and malignant pleural effusion. Eur Respir J 2010; 36: Suppl. 54, 227

Member's Comments

No comment yet.

Related content which might interest you: Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001 Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003 Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006 Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005 Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusions Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 Evaluation of pleural fluid levels and pleural-serum ratio of the tumor markers CEA, CA 15,3, CA 19,9, CA 72,4, CA 125 and CYFRA 21,1 in the diagnosis of malignant pleural effusion Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001 Diagnostic value of CYFRA 21-1, CEA, CA19-9, CA 15-3, and CA 125 assay in pleural effusions: analysis of 116 cases and review of the literature Source: Eur Respir J 2005; 26: Suppl. 49, 73s Year: 2005 The diagnostic value of mucinous carcinoma - associated antigen (MCA) testin differentiation of malignant from benign pleural effusion (PE) Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004 Diagnostic value of linear combination of CYFRA 21-1 and carcinoembryonic antigen in malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Late-breaking abstract: Tumor marker pattern in benign pleural effusion investigation. A case report of increased pleural CA 125 Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Use of carcinoembryonic antigen in pleural effusion for differential diagnosis of benign and malignant pleural effusion Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology Year: 2008 Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002 Malignant pleural mesothelioma: survival-predictive CT elements in 28 patients Source: Eur Respir J 2002; 20: Suppl. 38, 271s Year: 2002 CEA, Cyfra 21.1 and NSE levels in malignant and benign pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002